Skip to main content
. Author manuscript; available in PMC: 2013 Feb 15.
Published in final edited form as: J Vaccines Vaccin. 2012 Nov 20;3(7):1000160. doi: 10.4172/2157-7560.1000160

Figure 6.

Figure 6

Efficacy and immunogenicity of TC-83-based VLPV in a CBA/J-ML29 mouse model [57]. (A) Mice immunized with VLPV and ML29 (vaccine control) were fully protected against fatal challenge. (B) Mice immunized with ΔLGPfib VLPV induced stronger cell-mediated immunity in comparison with ML29- and LGPwt-immunized mice.